Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 507
Conférences

le (23m3s)

BRIO strategic challenges and the implementation of a translational culture in Bordeaux

About BRIO Siric challenges and actions  BRIO’s strategic objective is to strengthen Bordeaux’s leadership in Cancer Research through the creation of a dynamic cancer research community, the pursuit of scientific excellence and the establishment of state-of-the-art transversal platforms. To achieve these strategic objectives, great emphasis was placed over the last year in the consolidation of governance mechanisms conducive to an all-inclusive approach leading to a significant strengthening of relations between consortium members and local stakeholders. Capitalizing on these governance mechanisms, BRIO’s activities and financial interventions have been aligned with the ...
Voir la vidéo
Conférences

le (13m2s)

BRIO's facts and figures, structuration projects : Axe Cancer, translational research centerUpdate the implementation of BRIO

Update the implementation of BRIO Brio organisation is now fully up and running, and more than 100 research projects are currently active into the 6 integrated research programmes. In addition, major progresses were achieved at the level of the 7 strategic axes defined to structure and support cancer research in Bordeaux. The bioinformatics axis saw the recruitment of 4 bioinformaticians (2 funded by BRIO) and the creation of a transversal bioinformatics axis at the University. For the in-vivo research axis, a project to develop a translational research center is currently being developed ...
Voir la vidéo
Conférences

le (15m1s)

Standardizing G8 evaluation

Non-pharmaceutical innovations and public healthManagement of the frail elderly with cancer is a challenge. Beside a poor outcome as compared to younger subjects, physicians will face increased risk of treatment-induced toxicity but also unexpected adverse events because of the underlying comorbidities and potential major consequences of these toxicities on the outcome because of frailty. In depth evaluation of the patient through geriatric assessment has been demonstrated as predictive of these adverse events but is time-consuming so that only a minority of cancer treatment hospitals will be able to propose it. Screening is part of the solution and G8 one of ...
Voir la vidéo
Conférences

le (19m53s)

Curing leukemia ?

Non-pharmaceutical medical innovations and public healthThe use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has proven remarkably successful in chronic myeloid leukemia (CML) and long-term survival has become a reality. Despite this outstanding progress, detection of minimal residual disease precludes therapy termination in most TKI-receiving patients. CML has thus turned into a chronic illness, raising concerns about long-term safety, medication adherence and healthcare costs. Although treatment cessation may be feasible in few selected patients achieving deep molecular responses, a definitive cure remains elusive owing to the discovery that TKIs spare quiescent leukemic stem cells (LSC). Understanding mechanisms ...
Voir la vidéo

 
FMSH
 
Facebook Twitter Google+
Mon Compte